CAR-T cell therapy

The Cancer Grand Challenges initiative has announced the five global research teams who between them will receive $125 million to address unanswered questions. The winning teams, revealed in March, are addressing four major oncology challenges – solid tumours in children,…

CRISPR is a revolutionary gene-editing tool that allows scientists to cut DNA with extraordinary precision and make changes to the genome. The technology was a gift to cancer researchers, whose efforts to understand the roles played by different genes rely…

Chimeric antigen receptor (CAR) T cells, genetically engineered immune cells targeted to attack cancers, are one of the most exciting breakthrough cancer treatments in oncology today. After decades of incremental development, its clinical efficacy was shown in 2010, with the…

A CAR T-cell therapy first-in-human study demonstrated early signs of efficacy for patients with a range of solid tumours, including testicular and ovarian cancers. The study, presented at the American Academy of Cancer Research (AACR) 2022 Annual Meeting (8-13 April…

Like most 2020 meetings the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held 5-8 December, was hosted virtually. Due to meticulous planning, the format did not prevent delegates attending the largest gathering of the professional haematology community…

  The advent of chimeric antigen receptor T  cell (CAR T  cell) therapy generated great excitement in the field of onco-haematology. Clinical trials have shown remarkable results in patients with relapsed/refractory B  cell malignancies, and two CAR T  cell products…